Abivax is currently conducting five clinical trials to test the tolerability, safety and efficacy of its two product candidates ABX464 and ABX196.

The ongoing clinical trials conducted with ABX464 in ulcerative colitis (UC) and rheumatoid arthritis (RA) consist each of two parts, an induction phase and a subsequent maintenance phase.

Phase 2b clinical trials in ulcerative colitis

The Phase 2b study is conducted to evaluate the efficacy and the safety of ABX464, taken orally once daily by patients with moderate-to-severe ulcerative colitis. The induction study has been completed and the corresponding open-label maintenance trial is ongoing. No more patients can be included into this study.

Maintenance Study

Only patients who conclude the “induction phase” of a study have the possibility to roll over into the “maintenance phase”, where long-term effects of the treatment are evaluated.

Phase 2a clinical trials in rheumatoid arthritis

The induction study aims at investigating the safety and tolerability of 2 different doses of ABX464 taken orally once daily in combination with methotrexate. The trial is conducted in patients with moderate-to-severe active rheumatoid arthritis who had an inadequate response to methotrexate or/and to one or more anti-tumor necrosis factor alpha (TNFα) therapies.
The patient recruitment for this trial has been completed and closed.

Maintenance Study

Only patients who conclude the “induction phase” of a study have the possibility to roll over into the “maintenance phase”, where long-term effects of the treatment are evaluated.

Phase 1/2 clinical trial in hepatocellular carcinoma

This study evaluates the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma (HCC).

More Information

More information can be found on clinicaltrials.gov.

Important Information

Please note that the drug candidates ABX464 and ABX196 are at present in the clinical testing stage and subject to the regulations set by the competent authorities.

Abivax is legally not entitled to decide whether a patient is eligible to be included in the clinical trials that Abivax sponsors. The investigating physicians of the clinical study centers are the sole individuals competent for deciding whether a patient is eligible, according to the inclusion and exclusion criteria defined in the corresponding clinical study protocol.

Additionally, Abivax cannot communicate or interact with individual patients on the conduct or progress of the study. You will find all publicly available information under clinicaltrials.gov.